Climate Change Data

Environmental Metrics

Climate Goals & Targets

Environmental Challenges

• Limited History: The Company was only recently incorporated on 8 March 2019 and has no operating history and limited historical financial performance.
• Patent Rights: The Intellectual Property that will be assigned to the Company by The University of Birmingham, UK, comprises certain patent applications. There can be no guarantee that the Company’s patent applications will be successful and lead to granted patents.
• Litigation: As part of regular business activities, the Company is exposed to possible litigation risks including contractual disputes, occupational health and safety claims and employee claims.
• Technology Development & Commercialisation: Although Exenatide has already been approved for therapeutic use in humans, there is no guarantee that a reformulated Exenatide will receive regulatory approval.
• Intellectual Property: There is a risk that parties might knowingly or unknowingly infringe the Company’s intellectual property rights or that the Company may infringe the intellectual property rights of third parties.
• Reliance on Key Personnel: The Company is dependent on the principal members of its scientific and development team, the loss of whose services could materially adversely affect the Company.
• Clinical Validation: A core component of the Company’s strategy is the commercialisation and registration of its products. Such trials can be expensive, time consuming, may be delayed or may fail.
• Manufacturing: Whereas Exenatide has been produced on a commercial scale, the Company’s potential reformulated product(s) have not yet been produced on a large scale.
• Dependencies on Service Providers: The Company is dependent on contract service providers to perform many activities.
• Risk of Delay: The Company may experience delays in achieving a number of critical milestones.
• Sufficiency of Funding: Failure to obtain sufficient financing may result in delay or indefinite postponement of the Company’s activities.
• Competition: There is no assurance that competitors will not succeed in developing products that are more effective or economically viable.
• Research and development: There are many risks inherent in the development of biopharmaceutical products.
• Unforeseen expenditure risk: Expenditure may need to be incurred that has not been taken into account.
• New Business Initiatives: The Company may from time to time undertake new business initiatives.
• Foreign Currency and Currency Exchange Risk: There is potential that the Company’s revenue and expenditure may in the future be domiciled in various currencies other than Australian dollars.
• Absence of Dividends: The ability of the Company to pay dividends in the future is dependent on many factors.
• Liquidity Risk: If restriction obligations (escrow) are applied to Shares held by the existing shareholders, the remaining “free float” may be limited.

Mitigation Strategies

• The Board aims to manage these risks by carefully planning its activities and implementing risk control measures.

Supply Chain Management

Climate-Related Risks & Opportunities

Environmental Metrics

ESG Focus Areas

• Not disclosed

Environmental Achievements

• Not disclosed

Social Achievements

• Not disclosed

Governance Achievements

• Established a Diversity Policy, a Code of Conduct, a Whistleblower Protection Policy, and an Anti-Bribery and Anti-Corruption Policy.

Climate Goals & Targets

Environmental Challenges

• Not disclosed

Mitigation Strategies

• Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: ASX Corporate Governance Council's Corporate Governance Principles and Recommendations – 4th Edition

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Not disclosed

Awards & Recognition

• Not disclosed

Environmental Metrics

ESG Focus Areas

• Not disclosed

Environmental Achievements

• Not disclosed

Social Achievements

• Not disclosed

Governance Achievements

• Established a Diversity Policy, outlining a framework for establishing, achieving, and measuring diversity objectives, including gender diversity.

Climate Goals & Targets

Environmental Challenges

• Not disclosed

Mitigation Strategies

• Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: ASX Corporate Governance Council's Corporate Governance Principles and Recommendations – 4th Edition

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Not disclosed

Awards & Recognition

• Not disclosed

Environmental Metrics

ESG Focus Areas

• Governance

Governance Achievements

• Adopted a Corporate Governance Plan.
• Adopted a Board Charter outlining roles and responsibilities.
• Adopted a Diversity Policy.
• Implemented processes for evaluating Board, committee, and individual Director performance.
• Implemented processes for evaluating senior executive performance.
• Articulated and disclosed company values.
• Implemented a code of conduct for Directors, senior executives, and employees.
• Implemented a whistleblower policy.
• Implemented an anti-bribery and anti-corruption policy.
• Implemented processes to verify the integrity of corporate reports.
• Implemented a written policy for complying with continuous disclosure obligations.
• Implemented an investor relations program.
• Implemented processes to facilitate shareholder participation in meetings.
• Implemented processes to ensure substantive resolutions are decided by poll.
• Implemented processes to allow electronic communication with security holders.
• Implemented processes for overseeing the entity’s risk management framework.
• Adopted a separate Environmental, Social and Governance (ESG) Policy and ESG Charter.

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Environmental Metrics

ESG Focus Areas

• Environmental
• Social
• Governance

Governance Achievements

• Established an Environmental, Social and Governance Committee
• Adopted a Diversity Policy
• Implemented a Whistleblower Protection Policy
• Established an Anti-Bribery and Anti-Corruption Policy

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: ASX Corporate Governance Principles and Recommendations – 4th Edition